Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Epilepsia. 2019 Nov 22;60(12):2359–2369. doi: 10.1111/epi.16388

Figure 3. The CB2R specific antagonist, SR144528, increases seizure susceptibility.

Figure 3.

A. SR144528 significantly reduced latencies to the first MJ following PTZ administration in WT mice compared to vehicle-treated controls. B. WT mice treated with SR144528 exhibit significantly reduced latencies to the first GTCS following PTZ administration compared to vehicle-treated WT mice. SR144528 treatment did not affect latencies to the first MJ or GTCS in Cnr2−/− mutants. 2-way ANOVA with Tukey’s post-hoc comparison, n=8/group. C. WT mice treated with SR144528 exhibit significantly higher average Racine scores when compared to vehicle-treated WT mice. SR144528 treatment did not affect susceptibility to 6 Hz-induced seizures in Cnr2−/− mutants. Each symbol represents one mouse. 2-way ANOVA with Tukey’s post hoc comparison, n= 8/group. *P < 0.05, ***P < 0.001. Veh, vehicle; sr, SR144528. All error bars represent mean +/− SEM.